Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

CORAL GABLES, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases, today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate in two upcoming investor conferences:

• The H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. Catalyst’s pre-recorded presentation will be available for viewing on-demand beginning Monday, September 13, 2021, at 7:00 AM EDT for those registered for the event. Catalyst’s management will host virtual 1x1 meetings throughout the day.

• 2021 Cantor Virtual Global Healthcare Conference taking place September 27 – 30, 2021. Catalyst’s management will present on September 28th at 1:20 PM EDT and will host virtual 1x1 meetings throughout the day. The webcast will be available on the Company’s website and a replay will be accessible for at least 14 days.

The presentation will be available on the Investor section of the company's website promptly following the scheduled presentation times.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for Firdapse® (amifampridine) Tablets 10 mg for the treatment of adults with LEMS was approved in 2018 by the U.S. Food & Drug Administration ("FDA") and is commercially available in the United States. Further, Canada’s national healthcare regulatory agency, Health Canada, approved the use of Firdapse® for the treatment of adult patients in Canada with LEMS.

Firdapse® is currently being evaluated in clinical trials for the treatment of MuSK-MG and has received Orphan Drug Designation from the FDA for myasthenia gravis.

For additional information about the company, please visit www.catalystpharma.com.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for fiscal year 2020 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Source: Catalyst Pharmaceuticals

Investor Relations Contact:
Mary Coleman
Catalyst Pharmaceuticals
(305) 420-3200
Mcoleman@catalystpharma.com

Media Contact:
David Schull
Russo Partners
(212) 845-4271
david.schull@russopartnersllc.com